Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Phoebe Starr

Authored Items
Neoadjuvant Nivolumab plus Chemotherapy May Be a New Standard of Care in Resectable NSCLC
Phoebe Starr
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Lung Cancer
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO 2020
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Breast Cancer
SBRT plus Immunotherapy in Metastatic Renal-Cell Carcinoma Warrants Further Study
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Immunotherapy
Immune Checkpoint Inhibitor Does Not Improve Outcomes in Metastatic Prostate Cancer
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Prostate Cancer
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies, Renal-Cell Carcinoma
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Value-Based Care
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy By
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ASH 2019 Highlights
Improving Access to Genetic Cancer Screening in a Medically Underserved Community
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ACCC
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Lung Cancer
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives published on February 24, 2020 in ESMO
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Olaparib Improves Outcomes in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives published on November 25, 2019 in Lung Cancer
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Geriatric Cancer
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Prostate Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with BRCA Mutations
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pancreatic Cancer
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Prostate Cancer
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Renal-Cell Carcinoma
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Prostate Cancer
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Genitourinary Cancers
Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Renal-Cell Carcinoma
Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia
Phoebe Starr
Web Exclusives published on April 9, 2018 in Leukemia
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
Phoebe Starr
Web Exclusives published on April 9, 2018 in Lymphoma
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Immunotherapy
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Emerging Therapies
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Melanoma, Immunotherapy
Enzalutamide Safe for Patients at Increased Risk for Seizure
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Prostate Cancer
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TOP - May 2017, Vol 10, No 2 published on May 5, 2017 in Side-Effects Management, Side-Effects Management
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TOP - May 2017, Vol 10, No 2 published on May 5, 2017 in Side-Effects Management, Side-Effects Management
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives published on February 15, 2017 in Conference Correspondent, In the News
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives published on February 15, 2017 in Conference Correspondent, In the News
Duloxetine Helps Reduce Aromatase Inhibitor–Associated Joint Pain
Phoebe Starr
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Breast Cancer
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TOP - November 2016, Vol 9, No 4 published on November 4, 2016 in Hematologic Cancers
Price of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
TOP - August 2016, Vol 9, No 3 published on August 3, 2016 in Conference Correspondent
Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer
Phoebe Starr
TOP - May 2016, Vol 9, No 2 published on May 13, 2016 in Genitourinary Cancers
ABCs of Immunotherapy
Phoebe Starr
TOP November 2015 Vol 8 No 4 published on December 3, 2015 in Immunotherapy
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TOP - May 2015, Vol 8, No 2 published on May 1, 2015 in Genitourinary Cancers
Venetoclax Moves Forward in Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 published on February 12, 2015 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 published on February 12, 2015 in Supportive Care
Posttransplant Brentuximab: New Standard of Care for Hodgkin Lymphoma?
Phoebe Starr
TOP - February 2015, Vol 8, No 1 published on February 12, 2015 in Hematologic Cancers
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
Phoebe Starr
TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Genitourinary Cancers
Angiotensin System Inhibitors Extend Survival in Patients With Metastatic Renal Cell Carcinoma
Phoebe Starr
TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Genitourinary Cancers
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TOP - May 2013, Vol 6, No 2 published on June 3, 2013 in Breast Cancer
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
Phoebe Starr
TOP - December 2012 VOL 5, NO 8 published on December 20, 2012 in Genitourinary Cancers
Last modified: June 18, 2020